Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of “Buy” from Brokerages

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been given a consensus rating of “Buy” by the ten research firms that are currently covering the company, Marketbeat reports. Ten research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $73.00.

JSPR has been the topic of a number of research reports. BTIG Research started coverage on Jasper Therapeutics in a report on Monday, July 8th. They set a “buy” rating and a $90.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research note on Tuesday, August 13th. Evercore ISI reaffirmed an “outperform” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Monday, August 26th. Royal Bank of Canada lowered their target price on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a research note on Wednesday, August 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th.

Institutional Investors Weigh In On Jasper Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Rhumbline Advisers bought a new position in shares of Jasper Therapeutics during the second quarter valued at approximately $300,000. Virtu Financial LLC purchased a new stake in shares of Jasper Therapeutics in the 1st quarter worth about $306,000. American Century Companies Inc. boosted its stake in shares of Jasper Therapeutics by 27.1% during the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock valued at $322,000 after purchasing an additional 3,032 shares in the last quarter. Concurrent Investment Advisors LLC purchased a new position in shares of Jasper Therapeutics during the first quarter valued at about $599,000. Finally, Bank of New York Mellon Corp bought a new position in Jasper Therapeutics in the second quarter worth about $740,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Trading Down 0.1 %

Shares of NASDAQ JSPR opened at $18.83 on Monday. The business has a 50-day moving average of $19.66 and a 200-day moving average of $22.45. The firm has a market capitalization of $283.66 million, a price-to-earnings ratio of -3.34 and a beta of 2.22. Jasper Therapeutics has a 12 month low of $4.00 and a 12 month high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($1.09) by $0.12. On average, analysts predict that Jasper Therapeutics will post -4.16 earnings per share for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.